The U.S. Food and Drug Administration has accepted Genentech's supplemental biologics license application for Tecentriq in combination with chemotherapy to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE